Drug Policy Watch · State Brief 2026

West Virginia

Snapshot (structured)

Adult-use cannabis: Not legal. No legalization passed; a Democratic-sponsored constitutional amendment (HJR 37) was introduced in the 2026 session but did not advance.
Medical cannabis: Legal since 2017 (West Virginia Medical Cannabis Act); sales began in 2021.
Home grow: Prohibited, including for medical patients. A 2026 proposal to allow patient/caregiver cultivation did not pass.
Intoxicating hemp / hemp THC: Effectively prohibited for sale. Delta-8 and similar intoxicating cannabinoids banned (SB 546, 2023); intoxicating THCA also restricted.
Psychedelics: Not legal. A medical-psilocybin "trigger" bill (SB 906) passed both chambers and was approved by the Governor on March 27, 2026; it authorizes prescription psilocybin only after federal FDA approval and DEA rescheduling, so no in-state access opens until then.
Broad decriminalization: No. Cannabis possession is not decriminalized; West Virginia is among the states that have not decriminalized.
Harm reduction: Restricted. Syringe services operate under tight 2021 licensing limits; fentanyl test strips legal since 2024; naloxone widely available.
Governor (party): Patrick Morrisey (Republican), in office since January 13, 2025.
Legislature control: Republican supermajority in both chambers (Senate roughly 32 of 34; House roughly 91 of 100).
Citizen ballot initiatives allowed: No. West Virginia has no statewide citizen initiative process.
Enclosure pressure score: 4/5

Cannabis

West Virginia is a medical-only cannabis state. The West Virginia Medical Cannabis Act was enacted in 2017, and the first dispensaries opened in 2021. Adult-use cannabis is not legal, and possession is not decriminalized, leaving West Virginia among the minority of states that have neither legalized nor decriminalized cannabis (MPP; IndicaOnline).

Home cultivation is prohibited, even for registered medical patients (MPP blog).

Market structure: The program is regulated by the Bureau for Public Health within the Department of Health (formerly Department of Health and Human Resources). Statutory caps allow up to 10 grower permits, up to 10 processor permits, and no more than 100 dispensary permits. Application fees are $2,500 per dispensary and $5,000 per grower or processor; registration fees are $10,000 per dispensary location and $50,000 for growers and processors. A 10% excise tax applies at the dispensary level on gross receipts; medical cannabis is exempt from the 6% state sales tax once the excise tax is paid (WV Medical Cannabis Act / MPP; Cannabis CPA Tax 2025). The relatively low permit caps and high registration fees favor a small number of larger, capitalized operators. Specific MSO presence and vertical-integration details are unconfirmed in the sources reviewed.

A notable fiscal feature: as of late 2025, the program had collected roughly $34 million in taxes, fees, and interest that the state had not spent, partly due to official concern about federal prohibition. The money is statutorily intended to support drug-treatment programs (Mountain State Spotlight; Marijuana Moment).

Key 2026 actions: The House of Delegates passed HB 5260 in March 2026, which would allow licensed processors to manufacture and dispensaries to sell medical cannabis edibles (limited to lozenge or gelatin forms, geometric shapes only, capped at 10 mg THC per serving). West Virginia is one of only a small number of medical states that still ban edibles. The bill moved to the Senate; its final disposition for the 2026 regular session is unconfirmed in the sources reviewed, and the session has adjourned sine die (The Marijuana Herald; HB 5260 text).

Hemp

West Virginia has deliberately steered intoxicating hemp cannabinoids out of the open retail market and into its regulated medical program. Delta-8 THC was banned via Senate Bill 546 (2023), and Delta-10, HHC, THCP, THCB, and intoxicating THCA hemp products are treated as illegal to sell. Legal access to THC is largely confined to the state-licensed medical cannabis system (Burning Daily / BD Logistics; WestVirginiaStateCannabis.org).

Federal exposure: The intoxicating-hemp landscape is being reshaped at the federal level. The Continuing Appropriations Act signed November 12, 2025 redefined hemp so that total THC, including THCA, must not exceed 0.3% on a dry-weight basis, with the change taking full effect November 12, 2026. This federal redefinition is expected to close the "hemp loophole" for intoxicating cannabinoids in interstate commerce (Perkins Coie; Womble Bond Dickinson; AtlRx). Because West Virginia has already restricted intoxicating hemp, the federal change largely reinforces, rather than overturns, existing state policy. Specific 2026 West Virginia hemp legislation is unconfirmed in the sources reviewed.

Psychedelics

West Virginia has not decriminalized psilocybin or other psychedelics, and there is no therapeutic-access program. In the 2026 session, Senate Bill 906 (a "trigger" bill) passed both chambers and was approved by the Governor on March 27, 2026. It creates an exception in state law for prescription use of crystalline polymorph psilocybin, but only if and when psilocybin is approved by the U.S. Food and Drug Administration and rescheduled by the U.S. Drug Enforcement Administration; psilocybin otherwise remains Schedule I under state code (WTRF; WBOY; High Times). The "trigger" structure means no in-state access opens until federal approval occurs, so practical access remains years away despite enactment.

Broader drug policy

Decriminalization: There is no broad drug decriminalization in West Virginia, and cannabis possession remains a criminal matter.

Harm reduction: West Virginia's harm-reduction environment is restrictive. State law since 2021 (SB 334) imposed tight licensing and operational requirements on syringe services programs, which sharply reduced their number; by mid-2025 only about three syringe exchange programs operated statewide, including Milan Puskar Health Right in Morgantown (Mountain State Spotlight; NEXT Distro; Bluefield Daily Telegraph). Fentanyl test strips and other drug testing strips were removed from the paraphernalia definition by SB 269, signed February 2, 2024, making them legal (WDTV). Naloxone is widely available without a prescription at major pharmacy chains (CVS, Fruth, Kroger, Rite Aid) (WDTV).

Sentencing and overdose policy: The 2026 session featured a cluster of roughly six drug-focused bills emphasizing enforcement. Senate Bill 34 (Sen. Tarr) would create a mandatory three-year minimum prison sentence for first-offense possession of Schedule I or II substances, excluding cannabis. Senate Bill 117 (Sen. Tarr) would create a "Neighborhood Assistance and Rejuvenation Compact" rewarding informants who help secure drug-trafficking arrests, administered by the State Police, with reporting indicating it would be funded in part by a one-cent excise tax on opioid antagonists (such as Narcan) and fentanyl test strips. One bill in the package would end syringe exchange services as currently structured while retaining harm-reduction counseling (WDTV; SB 117 text; WV Gazette-Mail).

Treatment funding: As noted above, roughly $34 million in medical-cannabis revenue earmarked for drug treatment remained unspent as of late 2025 (Mountain State Spotlight).

Political landscape

Governor: Patrick Morrisey (Republican), in office since January 13, 2025 (Ballotpedia; Wikipedia).

Legislature: Republicans hold a supermajority in both chambers, reported at roughly 32 of 34 Senate seats and roughly 91 of 100 House seats; together Republicans hold about 123 of 134 legislative seats (West Virginia Watch). The 2026 elections put all 100 House seats and roughly 19 Senate seats on the ballot.

Reform actors: On the cannabis side, named Republican Delegate Jeff Eldridge led HB 5260 (edibles), and a companion Senate measure was carried by Senators Jack Woodrum (R), Bennett Queen (R), and Zachery Maynard (R) (source). Delegate Sean Hornbuckle (D) sponsored the 2025 adult-use constitutional amendment (HJR 27), with co-sponsors that 2025 reporting listed as Delegates Lewis, Pushkin, Hansen, and Garcia (HJR 27 text). On the enforcement side, Senator Tarr is pushing harsher possession penalties (SB 34) and an informant-reward program (SB 117). The specific committee chairs handling these bills (House Judiciary received HJR 37) are otherwise unconfirmed in the sources reviewed. No prominent named opponent of medical-cannabis expansion was identified in the sources reviewed (unconfirmed).

Ballot initiatives

West Virginia has no statewide citizen initiative or referendum process; voters cannot place statutes or constitutional amendments on the ballot by petition. Constitutional amendments reach the ballot only when the Legislature refers them. The 2026 HJR 37 (and 2025 HJR 27) sought legislative referral of an adult-use cannabis amendment to voters, but as legislatively originated measures they require a two-thirds vote of each chamber to reach the ballot, and neither advanced (LegiScan HJR37; The Marijuana Herald). There is no pending citizen-initiated measure because that mechanism does not exist in West Virginia.

Equity and expungement

West Virginia's medical cannabis statute does not include a robust social-equity licensing program comparable to those in some adult-use states; specific equity set-asides are unconfirmed in the sources reviewed. There is no automatic cannabis-conviction expungement. The only expungement pathway tied to cannabis reform is prospective and conditional: HJR 37 would have made prior convictions for possession of two ounces or less subject to dismissal or expungement by petition to the circuit court in the county of conviction, but only if the amendment were referred and approved by voters (LegiScan HJR37). Because that measure did not advance, no new cannabis expungement relief took effect. Petition-based, fee-bearing expungement disadvantages low-income and rural residents who lack legal assistance.

Market and barriers

Hard numbers (medical program): excise tax of 10% at the dispensary level; medical cannabis exempt from the 6% state sales tax once the excise tax is paid. Application fees: $2,500 per dispensary, $5,000 per grower or processor. Registration fees: $10,000 per dispensary location, $50,000 for growers and processors. License caps: up to 10 growers, up to 10 processors, no more than 100 dispensaries (MPP / WV Medical Cannabis Act; Cannabis CPA Tax). Capital and residency requirements and the exact current number of active licensees are unconfirmed in the sources reviewed. The program had collected about $34 million in cumulative revenue by late 2025 (Mountain State Spotlight).

Enclosure read

West Virginia sits near the heavily fenced end of the spectrum. Patients are confined to a small, capped, medical-only market: at most 10 growers, 10 processors, and 100 dispensaries, with five- and six-figure registration fees that price out small and community operators and concentrate the market among well-capitalized firms. Home cultivation is banned, so patients cannot opt out of the licensed supply chain. Edibles, a basic product category, were still prohibited as of the 2026 session despite a House-passed bill. Intoxicating hemp is squeezed out of independent retail and funneled toward the same regulated channel, and the November 12, 2026 federal redefinition will reinforce that closure. On the demand and harm-reduction side, the fencing is even sharper: syringe services are constrained by 2021 licensing rules down to roughly three programs statewide, and 2026 enforcement bills (mandatory minimums, informant rewards funded by a tax on naloxone and test strips) point toward further criminalization rather than openness. The state has no citizen initiative, so reform depends entirely on a Republican supermajority legislature that has so far declined to legalize or decriminalize. The main counterweights keeping this from a 5 are that medical access does exist and is functioning, fentanyl test strips are legal, and naloxone is broadly available. Net score: 4/5.

What to watch next

2026 regular session: convened January 14, adjourned March 14 (60-day session), now sine die. Bills that did not pass are dead for 2026 (Ballotpedia; West Virginia Watch).
HB 5260 (edibles): confirm final Senate disposition and whether it was signed; if it died, watch for reintroduction in 2027.
November 12, 2026: full effect of the federal hemp redefinition (THCA counted toward total THC), affecting any residual intoxicating-hemp commerce (Perkins Coie).
2026 elections: all 100 House seats and roughly 19 Senate seats on the ballot; composition shifts could affect 2027 reform odds.
The unspent ~$34 million cannabis fund: watch for legislative or executive action on disbursement.
Next regular session: expected to convene in January 2027 (date to be set by the legislative calendar).

Regulators

Cannabis (medical): Office of Medical Cannabis, within the Bureau for Public Health, West Virginia Department of Health (the former Department of Health and Human Resources was reorganized into separate departments effective 2024). Tax collection involves the West Virginia State Tax Department (WV Medical Cannabis Act / MPP).
Hemp: West Virginia Department of Agriculture administers the state hemp program (WV Code Article 19-12E) (WV Code 19-12E).
Drug scheduling and controlled substances: West Virginia Board of Pharmacy and state code (psilocybin remains Schedule I).
Harm reduction / overdose: West Virginia Department of Health (Bureau for Public Health); syringe services licensing handled at the state level with local approval requirements.
Enforcement programs: West Virginia State Police (would administer the SB 117 informant program if enacted).

Federal exposure (2026)

West Virginia's drug-policy posture is unusually exposed to 2026 federal moves, because the state has built almost everything it allows on top of federal categories it does not control.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I, and a broader DEA hearing opened June 29, 2026 (and may slip to 2027). For West Virginia this is the rare piece of good news for incumbents: the state is medical-only, so its licensed growers, processors, and dispensaries fall inside the medical category that gains relief from Internal Revenue Code Section 280E, which had barred ordinary business deductions for cannabis operators. That relief flows to the small set of capitalized firms the state's caps and fees already favor (up to 10 growers, up to 10 processors, up to 100 dispensaries, with five- and six-figure registration fees). Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover the state businesses themselves; it changes the tax math, not the legal status, so West Virginia operators still cannot bank or ship across state lines on the strength of it.

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Section 781, Rep. Andy Harris R-MD) narrows hemp to a total-THC standard, roughly 0.4 mg THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R.7010 delay was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. West Virginia had already steered intoxicating hemp cannabinoids (delta-8, delta-10, HHC, THCP, THCB, intoxicating THCA) out of open retail via SB 546 (2023) and related restrictions, funneling lawful THC access into the state-licensed medical program. The practical effect of the federal ban is therefore reinforcement rather than reversal: any residual intoxicating-hemp commerce that survived in gray channels is fenced off federally, and the only remaining lawful THC pathway in the state is the capped medical program. Small hemp retailers and independent cannabinoid sellers are the losers; the licensed medical incumbents inherit the demand.

Banking. SAFER Banking has stalled in Congress. With no federal safe harbor, West Virginia's licensed operators remain cash-heavy and underbanked, which compounds the high entry costs and further advantages well-capitalized firms that can absorb cash-handling risk and lending gaps. This also bears on the roughly $34 million in unspent medical-cannabis revenue: official wariness about federal prohibition, of which banking uncertainty is a part, is among the reasons cited for not disbursing the fund.

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers are intended to fast-track FDA review, but no psychedelic has been approved. West Virginia's SB 906, a conditional medical-psilocybin trigger bill, passed both chambers and was approved by the Governor on March 27, 2026; it opens a prescription pathway only if and when the FDA approves psilocybin and the DEA reschedules it. The state has thus pre-wired its access to the federal pathway: even though SB 906 is now law, no in-state access opens until the federal approval and rescheduling occur, which the 2026 EO accelerates but has not delivered.

Harm reduction. West Virginia's harm-reduction infrastructure is already constrained, roughly three syringe services programs statewide after the 2021 SB 334 licensing limits, even as the state carries one of the nation's heaviest overdose burdens. Fentanyl test strips are legal (removed from the paraphernalia definition by SB 269, signed February 2, 2024). This makes the April 24, 2026 SAMHSA guidance, which bars federal funds for fentanyl test strips, clean syringes, and sterile water while still supporting naloxone, a direct hit: the few remaining syringe programs and any test-strip distribution that leaned on federal dollars lose that support, and the state's restrictive licensing regime leaves little slack to backfill. Naloxone remains federally supported and broadly available in West Virginia, so the surviving federal lever is the one the state already leans on hardest.

Net read: rescheduling hands West Virginia's medical incumbents a tax break, while the hemp cliff, stalled banking, the conditional psychedelics trigger, and the SAMHSA harm-reduction cuts all push in the enclosing direction, fencing out small actors, hemp sellers, and harm-reduction providers and reinforcing a closed, medicalized, incumbent-friendly system.

Patient access and rights

This section covers what West Virginia law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): West Virginia has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; West Virginia is not among them. The absence is the finding: a West Virginia patient has no enforceable right to use their medicine in a hospital today.

Broader protections: West Virginia protects a patient in one of the six areas, employment. W. Va. Code Section 16A-15-4(b)(1) bars an employer from discharging or discriminating against an employee solely for being a certified patient. A review of the surrounding sections found no protection for housing, parenting, an organ transplant list, or school enrollment; the general non-denial language in 16A-15-4(a) does not reach those areas. Those gaps are the finding.

Out-of-state patients: West Virginia's statute contemplates reciprocity for terminally ill cancer patients, but no reciprocity agreements are in place, so in practice an out-of-state card is not recognized for purchase.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and West Virginia has not enacted a Ryan's Law. The broader protections above are a creature of West Virginia law, not federal law.

Sources: West Virginia patient protections, W. Va. Code Section 16A-15-4.

Analysis: the enclosure read in depth

Who is fenced out. In West Virginia the fence runs almost all the way around. There is no adult-use market, so anyone who is not a registered patient has no lawful supply. Home grow is banned even for patients, so patients cannot opt out of the licensed chain. The medical market itself is capped (up to 10 growers, 10 processors, 100 dispensaries) and gated by five- and six-figure registration fees, which price out small, community, and rural operators and concentrate supply among well-capitalized firms; edibles, a basic product category, were still prohibited as of the 2026 session despite a House-passed bill (HB 5260). Intoxicating hemp, the usual low-barrier on-ramp for small sellers, is banned at retail and now federally recriminalized. Harm-reduction providers are fenced by 2021 licensing limits down to about three syringe programs. And the political fence is structural: a Republican supermajority controls both chambers (roughly 32 of 34 Senate, 91 of 100 House), and West Virginia has no citizen initiative, so there is no petition route around the legislature. Reform depends entirely on a legislature that has so far declined to legalize or decriminalize.

State-plus-federal interaction. The two layers reinforce each other rather than offset. The state pre-closed intoxicating hemp; the November 12, 2026 federal standard locks that closure in. The state built a capped medical-only program; federal rescheduling rewards exactly that program's incumbents with 280E relief, deepening the cost advantage that the caps and fees already created. The state pre-wired psychedelics to a federal trigger (SB 906); the federal pathway has not opened, so access stays at zero. The state already runs a thin, tightly licensed harm-reduction network; the April 2026 SAMHSA cuts pull federal money out from under it. In each case the federal lever moves in the same direction as state policy: toward a controlled, medicalized, incumbent-favoring system and away from open access or low-barrier participation. The only divergence, 280E relief, benefits incumbents, not new entrants, so it does not loosen the fence.

What to watch. Whether HB 5260 (edibles) is revived in 2027 and whether any home-grow or patient-cultivation proposal advances, since those are the few moves that would let patients out of the closed chain. SB 906 was enacted March 27, 2026 as a contingent trigger; more decisively, whether the federal FDA/DEA psychedelics pathway actually opens, since no in-state access starts until it does. The disbursement of the roughly $34 million unspent cannabis fund, a tell on official appetite for spending in a federally uncertain space. The fate of the 2026 enforcement cluster (SB 34 mandatory minimums, SB 117 informant rewards funded partly by a tax on naloxone and test strips), which would tighten the fence further. And the 2026 elections (all 100 House seats, roughly 19 Senate seats), which set the 2027 reform odds. On the federal side, the November 12, 2026 hemp effective date and any movement on SAFER Banking or the broader DEA cannabis hearing.

Scarcity of commons counter-moves. There is very little working against enclosure here. There is no citizen initiative to force change from below, no adult-use market, no home grow, no decriminalization, and no robust social-equity licensing program (equity set-asides are unconfirmed in the sources reviewed). The genuine counterweights are narrow: a functioning medical program does exist, fentanyl test strips are legal, and naloxone is broadly available and federally still supported. These keep some access and some harm reduction alive, but none of them open the market to small actors or create a participatory commons; they are a floor, not a door.

Justifying the score. The enclosure pressure score is 4 of 5. Almost every dimension points to heavy fencing: medical-only with no adult-use, banned home grow, capped and high-fee licensing, banned edibles (as of the session), intoxicating hemp banned and now federally recriminalized, harm reduction squeezed and newly exposed to federal funding cuts, an enforcement-leaning 2026 legislative cluster, a Republican supermajority, and no citizen-initiative escape valve. The score is held at 4 rather than 5 only because a real medical program functions, test strips are legal, and naloxone is broadly available; if edibles stay banned, syringe programs contract further under the SAMHSA cuts, and the enforcement bills advance, the case for a 5 strengthens.

Active legislation (2026)

The 2026 regular session ran January 14 to March 14 and has adjourned sine die, so bills that did not pass are dead for the session. The table below lists significant cannabis, hemp, psychedelic, and drug-policy bills. This list is not exhaustive; for the full set and live status, see the LegiScan WV tracker, the WV Legislature bill status site.

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HB 5260	Allow medical cannabis edibles (lozenge/gelatin, 10 mg THC/serving)	House (orig.)	Passed House Mar 2026; sent to Senate; final 2026 outcome unconfirmed	Lead sponsor Del. Jeff Eldridge (R) plus eight other Republican delegates (source)
HJR 37	Constitutional amendment to legalize adult cannabis (up to 2 oz or 4 plants), authorize sales, allow petition-based expungement	House (orig.)	Introduced Feb 5, 2026; referred to House Judiciary; did not advance	Four Democratic sponsors (named legislators unconfirmed) (LegiScan HJR37)
SB 906	"Trigger" bill: prescription psilocybin exception contingent on FDA approval and DEA rescheduling	Senate (orig.)	Passed both chambers March 14, 2026 and was approved by the Governor March 27, 2026; the prescription-psilocybin trigger provision is enacted (contingent on FDA approval and DEA rescheduling). (source)	Sponsor(s) unconfirmed (WTRF)
SB 34	Mandatory three-year minimum for first-offense Schedule I/II possession (excludes cannabis)	Senate (orig.)	Introduced 2026; status unconfirmed	Sen. Tarr (WDTV)
SB 117	"Neighborhood Assistance and Rejuvenation Compact": informant rewards for drug-trafficking arrests; funded partly by tax on naloxone/test strips	Senate (orig.)	Introduced 2026; status unconfirmed	Sen. Tarr (SB 117 text)
HB 4371	Cannabis/hemp-related (specific topic unconfirmed)	House (orig.)	Introduced 2026; status unconfirmed	Sponsor(s) unconfirmed (HB 4371 text)

Note: A separate 2026 proposal to allow registered patients and caregivers to grow up to 10 plants (no more than five mature) was discussed; its specific bill number and sponsor are unconfirmed in the sources reviewed (MPP blog).

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →